BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34530752)

  • 1. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
    Shi C; Liu S; Tian X; Wang X; Gao P
    BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
    Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma.
    Chen Y; Li ZY; Zhou GQ; Sun Y
    Clin Cancer Res; 2021 Jan; 27(1):330-341. PubMed ID: 33097495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
    Huang J; Liang B; Wang T
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
    Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
    Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel comprehensive immune-related gene signature as a promising survival predictor for the patients with head and neck squamous cell carcinoma.
    Fang R; Iqbal M; Chen L; Liao J; Luo J; Wei F; Wen W; Sun W
    Aging (Albany NY); 2021 Apr; 13(8):11507-11527. PubMed ID: 33867351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
    Poeta ML; Manola J; Goldwasser MA; Forastiere A; Benoit N; Califano JA; Ridge JA; Goodwin J; Kenady D; Saunders J; Westra W; Sidransky D; Koch WM
    N Engl J Med; 2007 Dec; 357(25):2552-61. PubMed ID: 18094376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer.
    Caponio VCA; Troiano G; Adipietro I; Zhurakivska K; Arena C; Mangieri D; Mascitti M; Cirillo N; Lo Muzio L
    Br J Cancer; 2020 Oct; 123(8):1302-1314. PubMed ID: 32684626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
    Hu R; Lu M; She L
    Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
    El Baroudi M; Machiels JP; Schmitz S
    Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL
    Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constructing a prognostic model for head and neck squamous cell carcinoma based on glucose metabolism related genes.
    Liu Y; Liu N; Zhou X; Zhao L; Wei W; Hu J; Luo Z
    Front Endocrinol (Lausanne); 2023; 14():1245629. PubMed ID: 37876534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
    Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
    Front Immunol; 2022; 13():975847. PubMed ID: 36091055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.
    Ganci F; Sacconi A; Bossel Ben-Moshe N; Manciocco V; Sperduti I; Strigari L; Covello R; Benevolo M; Pescarmona E; Domany E; Muti P; Strano S; Spriano G; Fontemaggi G; Blandino G
    Ann Oncol; 2013 Dec; 24(12):3082-8. PubMed ID: 24107801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
    Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
    Front Immunol; 2020; 11():590618. PubMed ID: 33391264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer.
    Zhang Y; Lin A; Li Y; Ding W; Meng H; Luo P; Zhang J
    Front Cell Dev Biol; 2020; 8():608969. PubMed ID: 33363171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.